Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	54.39B +8.8%
Revenue (ttm)	5.06B +31.0%
Net Income	767.58M +119.2%
EPS	0.69 +123.0%
Shares Out	1.11B
PE Ratio	71.20
Forward PE	62.06
Dividend	0.27 (0.54%)
Ex-Dividend Date	May 15, 2026

Volume	3,590,111
Open	49.99
Previous Close	47.80
Day's Range	47.55 - 50.37
52-Week Range	40.70 - 62.65
Beta	-0.18
Analysts	Strong Buy
Price Target	99.08 (+102.08%)
Earnings Date	Aug 14, 2026

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmac...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5,597
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2025, SHE:002653's revenue was 4.39 billion, an increase of 17.91% compared to the previous year's 3.72 billion. Earnings were 259.58 million, a decrease of -34.36%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error